Skin Cancer Clinical Trials & Research at St. Joseph Health Medical Group

St. Joseph Health Medical Group is currently enrolling patients for the following skin cancer clinical trials:

A Phase 2, Open-label, Single-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (KEYNOTE-629)

Phase II

The goal of this single arm study is to test the clinical activity of pembrolizumab for unresectable and/or metastatic cutaneous Squamous Cell Carcinoma, a disease with limited treatment options and a significant unmet clinical need.

Treatment agent: Pembrolizumab
PI: Ian Anderson, MD
Study Coordinator: Tracy Foster // Tracy.Foster@stjoe.org // (707) 521-3836
Resources and Links: clinicaltrials.gov NCT No: NCT03284424

Our Locations